Contact us  HCVets@gmail.com

Follow us on Facebook

One on One Support

Health Concerns
VA Issues  


Information:
Notice: Website under construction,
Contact
HCVets@gmail.com  
 

May 2014 VA Hep C Treatment Guidelines
UPDATE: Feb 26, 2016-
Funding and Prioritization Status Update

UPDATE: March 2016
VA Hep C Treatment Guidelines
VA to treat all vets in system
 

By Judith Graham
VA Extends New Hepatitis C Drugs to All Veterans in Its Health System

 
Orange Count Registry
Vietnam vets blame 'jet guns' for their hepatitis C
By Lily Leung Feb. 14, 2016 
 
CBS News Investigates
Congress outraged over hepatitis C treatment VA can't afford
Dr. Raymond Schinazi played a leading role developing a drug that cures hepatitis C while working seven-eighths of his time for the VA
 
ibtimes.com| By amynordrum
 


Hepatitis C drug costing VA, DoD millions
By Patricia Kime, Staff writer
We're looking at a company who is milking a cash cow for everything it's worth," Sanders said. 
 


VA to outsource care for 180,000 vets with hepatitis C
Dennis Wagner, The Arizona Republic 12:27 a.m. EDT June 21, 2015
 


VA to outsource care for 180,000 vets with hepatitis C
, The Republic | azcentral.com 11:51 a.m. MST June 19, 2015
Dr. David Ross, the VA's director public-health pathogens programs, resigned from the working group. "I cannot in good conscience continue to work on a plan for rationing care to veterans," he wrote.
 


VA Region Stops Referring Patients To Outside Hospitals Thanks To Budget Shortfall
Michael Volpe Contributor ...According to a memo — the entire region has been forced to stop all “non-VA care” referrals due to a budget shortfall.
 

DisabledVeterans.org
OIG INVESTIGATES VA CHOICE PROGRAM PROBLEMS
Sen. Mark Kirk admitted the VA Choice Program is a failed joke in a letter to Secretary Bob McDonald despite attempts to fix it.
 

 
Denied Hep C VA dental care?
Please click here

 
Dried Hepatitis C Blood Exposure 11/23/2013 Weeks later inconspicuous blood transmits virus and more likely to cause accidental exposures to Hep C
 

Lack of Standards for
Mass Vaccinations
1970 Jetgun Nursing Instructions
 

2014 AASLD Study Hepatitis C not an STD

Home
Test the Rest Campaign
Documentation & Surveillance Alerts
Military Hepatitis History  
Understanding The Liver 
VA Flow Sheet for Cirrhosis
VA Defines Risk Factors
 
Hep C & Pro-Prebiotic
Need to know-Grassroots Research
 
Blog Another12Weeks
One Vets' Journey Though Treatment
 

 Ask NOD
 What Would Veterans Do?
Blog for VA Claims
 


Help with VA Claims
 


 
Info: Plan Backfires-
VBA Fast Letter Boost Claims
 
Legal- Fed Regs state:
Judge decision may be relied upon
Cotant v. Principi, 17 Vet.App. 116, 134 (2003),
 
Service Connected Claims
# 1 Conclusion of Law 
# 2 Conclusion of Law 
 
More Claims
Jetgun Decisions
Hep C Decisions
 
Search Board of Appeals Website
BVA Jetgun Decisions
BVA Hepatitis C Decisions

Great Advice!  
After the jetgun win
What to do next

 

 

  • David Burger

      Affiliations

    • Department of Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Pharmacy, Radboud University Nijmegen Medical Center, Internal Code 864, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands. Tel.: +31 24 3616405; fax: +31 24 3668755.
    ,
  • David Back

      Affiliations

    • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    ,
  • Peter Buggisch

      Affiliations

    • Livercenter Hamburg, IFI, Asklepiosklinik St. Georg, Hamburg, Germany
    ,
  • Maria Buti

      Affiliations

    • Liver Unit, Hospital Universitari Valle Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain
    ,
  • Antonio Craxí

      Affiliations

    • Department of Gastroenterology and Hepatology, DIBIMIS, University of Palermo, Palermo, Italy
    ,
  • Graham Foster

      Affiliations

    • Queen Mary’s University of London, UK
    ,
  • Hartwig Klinker

      Affiliations

    • Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
    ,
  • Dominique Larrey

      Affiliations

    • Dominique Larrey Liver Unit and INSERM Unit 632, Saint-Eloi Hospital, Montpellier University, Montpellier, France
    ,
  • Igor Nikitin

      Affiliations

    • Russian State Medical University, Department of Internal Diseases, Moscow, Russian Federation
    ,
  • Stanislas Pol

      Affiliations

    • Unité d’Hépatologie, Hôpital Cochin, AP-HP, INSERM U1016, and Université Paris-Descartes, Paris, France
    ,
  • Massimo Puoti

      Affiliations

    • Department of Infectious Diseases, A.O. Ospedale Niguarda Cà Granda, Milan, Italy
    ,
  • Manuel Romero-Gómez

      Affiliations

    • UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Spain
    ,
  • Heiner Wedemeyer

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, University of Hannover, Hannover, Germany
    ,
  • Stefan Zeuzem

      Affiliations

    • Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany

Received 17 August 2012; received in revised form 22 October 2012; accepted 25 October 2012. published online 06 November 2012.

Article Outline

  • Summary
  • Introduction
  • Pharmacokinetics of anti-HCV agents
  • Concentration, effect relationships
  • Immunosuppressive agents (including steroids)
  • Antimicrobial agents (non-HIV)
  • Methadone/buprenorphine
  • Antidepressants
  • Sedatives
  • Statins
  • Cardiovascular agents (other than statins)
  • Antidiabetics
  • Other agents
  • Limitations of current drug interaction data
  • Conclusions
  • Financial support
  • Conflict of interest
  • References
  • Copyright

Abbreviations: HCV, hepatitis C virus, DAAs, direct-acting antivirals, HIV, human immunodeficiency virus, SPCs, summary of product characteristics, Peg, polyethylene glycol, BID, twice daily, AKR, aldo-ketoreductases, P-gp, P-glycoprotein, AUC, area under the plasma concentration vs. time curve, FDA, Food and Drug Administration, EMA, European Medicines Agency, TDM, therapeutic drug monitoring, CYP, cytochrome P450, ECG, electrocardiogram, UGT, UDP-glucuronosyltransferase, ACE, angiotensin converting enzyme, AT1, angiotensin II receptor, PDE5, phosphodiesterase type 5, BOC, boceprevir, TVR, telaprevir, RBV, ribavirin, IFN, interferon

Keywords: Drug interactions, Hepatitis C virus infection, Boceprevir, Telaprevir, Pharmacokinetics

Related Information
Steer clear of moxifloxacin and levofloxacin if you are older or have a compromised liver as most of us do. Read and heed. HCV & Depression Meta-Analysis